Analyze.

Reset.

Revolutionize.​

man on horse

Revolo Biotherapeutics, formerly Immune Regulation

About

If you’re looking for a typical biotechnology company, you’ve come to the wrong place.

We are a revolutionary biotherapeutics company and our mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission

How?

By developing therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. A goal that others haven’t been able to reach.

Why?

Existing therapies for autoimmune and allergic diseases require frequent chronic dosing, provide only short-term disease remission in a limited number of patients and suppress the immune system, ultimately putting patients at risk of developing serious infections and life-threatening side effects.

Product Development Landscape

Product Development Landscape

Our two platform drug candidates, ‘1805 and ‘1104, reset the immune system after only a single administration in an unmatched way. They have demonstrated unique efficacy and safety in preclinical and human studies without immune suppression. Given our disease-agnostic approach, we are uniquely positioned as Revolutionaries in the development of drugs for various autoimmune and allergic diseases.

‘1805
is a first-in-class modified analogue of the endogenous Binding Immunoglobulin Protein, BiP, a key molecule in immune system function. We are advancing ‘1805 into a second Phase 2 clinical study for moderate to severe rheumatoid arthritis as well as a Phase 2 clinical study in the rare disease uveitis, which is the leading cause of blindness.
‘1104
Is a first-in-class peptide derived from the immuno-regulatory protein mTB chaperonin 60.1. We are advancing ‘1104 through a Phase 2 trial in patients with eosinophilic esophagitis (EOE) and a Phase 2 allergen sensitivity study. ‘1104 is additionally being evaluated in an additional Phase 1 study to support future phase 2 clinical trials.
Previous
Next

Leadership

Industry veterans | Immunology and allergic disease experts | dedicated revolutionizers

Our team members have highly successful track records in funding and executing drug development and commercialization plans. With decades of experience in clinical development, we are ready to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission.

Our Krewe

Jonathan Rigby

Jonathan Rigby, mba

Group Chief Executive Officer
Perry Calias

Perry Calias, ph.d.

Chief Operating Officer
Jones Bryan

Jones W Bryan, ph.d.

Chief Business Officer
Roly Faulkes

Dr. Roly Foulkes

Chief Scientific Officer
Jeff Myers

Jeff Myers, m.d., ph.d.

Chief Medical Officer
Clare Burgess

Dr. Clare Burgess

Chief Development Officer
Nancy Vinh

Nancy Vinh

VP of Clinical Operations
Marylyn Rigby

Marylyn Rigby

VP of Marketing & Investor Relations

Board of Directors

Peter Greenleaf

Chairman

Jonathan Rigby, mba

Group Chief Executive Officer

Dr. Isaac Cheng, m.d.

Non-Executive Director

Michael Albisser

Non-Executive Director

Investors

Get our brief summary investor deck.

If you’d like to get more information we’d love to provide it, so don’t hesitate to contact us!
If you’d like to get more information we’d love to provide it, so don’t hesitate to contact us!

Contact Us

We are always looking to revolutionize treatment paradigms and happy to chat with you about yours or ours. Interested? We are!

Be sure to Contact Us


Scroll to Top

Michael Albisser

Non-Executive Director​

Michael is a partner of Metellus, a Zurich and London-based venture capital firm investing in technology and life sciences with ground-breaking potential. Having more than 25 years of experience in the finance area he is responsible for finance, tax, and deal structures. He serves on the board of various venture-backed companies.

Dr. Isaac Cheng, m.d.

Non-Executive Director

Dr. Isaac Cheng is currently an investment professional at Morningside, a venture capital and private equity institution based in China. Dr. Cheng focuses primarily on biopharmaceutical and healthcare investments. He has served on numerous public and private company boards.

Peter Greenleaf

Chairman

Peter Greenleaf currently serves as the chief executive officer (CEO) and member of the Board of Directors of Aurinia, (NASDAQ: AUPH / TSX: AUP), an autoimmune therapeutics company. He has held several other CEO and chairman roles. He is also currently a member of the Board of Directors of Antares Pharmaceuticals, Inc. (NASDAQ: ATRS) and Chairman of the Board of Directors of Biodelivery Sciences International, Inc. (NASDAQ: BDSI).

Marylyn Rigby

VP of Marketing and Investor Relations

Marylyn Rigby is an experienced pharmaceutical, biotech, and drug delivery professional. In addition to her expertise in marketing, public and investor relations, she has a successful track record with business development, licensing, public and private equity financing, strategy and other key corporate functions.

Nancy Vinh

VP of Clinical Operations

Nancy Vinh brings over 20 years of experience in managing early and late phase, international clinical trials for drugs, biologics, cell therapy and combination products across a wide range of therapeutic areas to the team. She has served as head of clinical operations and led registrational and label expansion trials execution.

Dr. Clare Burgess

Chief Development Officer

Dr. Clare Burgess has 24 years of experience in clinical drug development as a pharmacologist and has worked across a wide range of therapeutic areas within the pharmaceutical industry. She has held multiple leadership roles and has led multidisciplinary teams across the world.

Jeff Myers, m.d., ph.d

Chief Medical Officer

Jeff Myers, M.D., Ph.D., has 20 years of experience in medical affairs, regulatory and clinical development within the biopharmaceutical industry, with focuses on cardiovascular, pulmonary, oncology, and inflammatory diseases.

Before entering the industry, he practiced as a congenital cardiac surgeon and served as the chief of pediatric cardiac surgery at Massachusetts General Hospital and as Associate Professor of Surgery at Harvard Medical School.

Dr. Roly Foulkes

Chief Scientific Officer

A true drug discoverer, Dr. Roly Foulkes has 25 years of experience building and delivering innovative therapeutic portfolios within the immunology and inflammatory disease space. He has a strong record advising small and medium sized immunology biopharma companies in developing competitive therapeutic strategies and bringing new innovative molecules to the clinic.

Jones w (woody) Bryan, ph.d.

Chief Business Officer

Jones (Woody) Bryan, Ph.D., brings almost 30 years of experience in the healthcare industry to the team, having led successful business development operations in both private and public pharma and biotech companies.

Perry Calias, ph.d.

Chief Operating Officer

Perry Calias, Ph.D., brings over 25 years of experience in pre-clinical and clinical development, CMC and global regulatory submissions across the drug and device sectors of healthcare. He has held numerous executive positions leading clinical and non-clinical operations, with a strong focus on diseases of the central nervous system and rare diseases.

Jonathan Rigby, mba

Group Chief Executive Officer

As employee #1 of Revolo Biotherapeutics in the US, Jonathan Rigby has led the company through substantial and rapid growth. He brings three decades of experience creating value and opportunities for companies in the pharmaceutical, biotech and drug delivery technology industry.